skip to content

Wellcome-MRC Cambridge Stem Cell Institute

 
Coronavirus image. Credit: CDC

The Cambridge Stem Cell Institute works with scientists in Cambridge and around the world in an effort to fight the COVID-19 pandemic.


As the world began to shut down in early 2020, CSCI researchers mobilised their expertise to contribute to the global efforts to tackle the virus. Some returned to active clinical duties, while others committed their research to better understanding the virus, from cardiovascular dysfunction to immune responses.

See how our teams engaged in #ResponsiveResearch 

 

CSCI Research Highlights:

 

Additional Research:

Professor Robin Franklin's lab and collaborators hypothesises the genetic and structural similarities between SARS-CoV-2 and measles, mumps, and rubella (MMR). Find out more in an interview with Dr Adam Young.

Dr Fotios Sampaziotis and Prof Ludovic Vallier’s labs have been using organoids as a platform to study COVID-19 screen compounds. A pre-print of this work can be found here.

Dr Cédric Ghevaert’s group is working with the University of Bristol on a project investigating viral interactions with megakaryocytes. Find out more in our interview with the Ghevaert group.

Professor Bertie Göttgens is part of a team researching the factors that influence the immune response between adults and children, offering insight to the innate differences present in paediatric patients leading to typically milder effects of the virus in children than in adults.

Professor David Rowitch's lab is working on a project to test an alternative enzyme to enhance COVID-19 antibody testing. This pilot project will serve as a proof of concept, providing a potentially valuable resource and alternative in COVID-19 antibody screenings.

Professor George Vassiliou’s lab is investigating the hypothesis that clonal haematopoiesis may be linked to increased severity of COVID-19.

Dr Ingo Ringshausen's lab is carrying out a project aiming to harness the inherent immunosuppressive properties of allogenic mesenchymal stem cells (MSCs) which can be used to treat severe inflammation in the lungs.